Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

neoplasms/tyrosine

Link salvestatakse lõikelauale
Leht 1 alates 1002 tulemused
The present application is a National Phase of International Application No. PCT/EP2005/011304 filed Oct. 20, 2005 and claims priority to German Patent Application No. 10 2004 054 215.5, filed Nov. 10, 2004. The contents of both applications are expressly incorporated herein by reference in their
CROSS-REFERENCE TO RELATED APPLICATIONS This application is a U.S. national stage filing under 35 U.S.C. .sctn. 371(c), of International Application No. PCT/EP2015/061569, filed on May 26, 2015, which claims foreign priority of U.K. Patent Application No. 1409488.2, filed on May 28, 2014. The entire

Protein tyrosine phosphatase mutations in cancers

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This application incorporates a 502 KB text file named "seqlst00631" created Jul. 22, 2010, which is the sequence listing for this application. TECHNICAL FIELD OF THE INVENTION This invention is related to the area of cancer. In particular, it relates to diagnosis, prognosis, treatment, drug

Protein tyrosine phosphatase mutations in cancers

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
TECHNICAL FIELD OF THE INVENTION This invention is related to the area of cancer. In particular, it relates to diagnosis, prognosis, treatment, drug discovery, target discovery, clinical testing for cancer. BACKGROUND OF THE INVENTION Phosphorylation of tyrosine residues is a central feature of most

Methods for identifying a tyrosine phosphatase abnormality associated with neoplastic disease

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION Protein tyrosyl phosphorylation is an important cellular regulatory mechanism. Much work has implicated protein tyrosine kinases (PTKs) in the control of cell proliferation and differentiation. Many PTKs, when mutated and/or captured by retroviruses, can promote

AKT tyrosine 176 phosphorylation cancer biomarker

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF INVENTION This invention relates to methods and compositions for the diagnosis, classification, and treatment of cancer. More specifically, this invention is a method of identifying cancer using novel protein phosphorylation status. BACKGROUND OF THE INVENTION The intracellular tyrosine

Tyrosine kinase receptor antagonists and methods of treatment for breast cancer

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION Many tumor cells depend on the activity of tyrosine kinases, which act, among other functions, to depress apoptosis in the cell. The tyrosine kinases are usually overproduced in malignant cells, which contributes to the cell's ability to resist apoptosis. Modulating the

Method for treating cancer using a tyrosine protein kinase inhibitor

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION It is presently known that many human diseases are caused at least in part by proteins present in the cells of the afflicted individual. For example, certain proteins encoded by oncogenes are known to be responsible for the production of cancer in humans. Included among

Tyrosine-phosphorylated WBP2, a novel cancer target and biomarker

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
CROSS-REFERENCE TO RELATED APPLICATION This application is a national stage filing under 35 U.S.C. .sctn.371 of international application PCT/SG2011/000293, filed Aug. 25, 2011, which was published under PCT Article 21(2) in English, and claims the benefit of Singapore Patent Application No.
TECHNICAL FIELD The present invention concerns the technical field of the pharmaceutical industry. In particular, the invention relates to compounds with tyrosine kinase inhibiting activity for use in the treatment of cancer in association with a defined dietetic regimen. PRIOR ART Molecularly
TECHNICAL FIELD The present invention concerns the technical field of the pharmaceutical industry. In particular, the invention relates to compounds with tyrosine kinase inhibiting activity for use in the treatment of cancer in association with a defined dietetic regimen. PRIOR ART Molecularly

Combination therapy for cancer using HSP27 inhibitor and EGFR tyrosine kinase inhibitors or anti-folates

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION This application relates to combination therapy for the treatment of cancer using inhibitors of heat shock protein 27 (Hasp 27) and an epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) such as erlotinib, or antifolates such as pemetrexed. BACKGROUND OF THE

Method for suppressing receptor tyrosine kinase-mediated pro-survival signaling in cancer cell

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
CROSS REFERENCE TO RELATED APPLICATIONS This application is a National Stage of International Application No. PCT/JP2011/080083 filed Dec. 26, 2011, claiming priority based on Japanese Patent Application No. 2010-290373 filed Dec. 27, 2010, the contents of all of which are incorporated herein by

Treating cancers associated with overexpression of class I family of receptor tyrosine kinases

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
TECHNICAL FIELD This invention is directed to treatment of class I family of receptor tyrosine kinases overexpressing cancers. BACKGROUND OF THE INVENTION The class I family of receptor tyrosine kinases is described in Reese, M. D., et al, Stem Cells, 15, pages 1-8 (1997), the whole of which is

Dihydropyrazole derivatives as tyrosine kinase modulators for the treatment of tumors

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION The invention had the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments. The present invention relates to compounds and to the use of compounds in which the inhibition, regulation and/or
Liitu meie
facebooki lehega

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

  • Töötab 55 keeles
  • Taimsed ravimid, mida toetab teadus
  • Maitsetaimede äratundmine pildi järgi
  • Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
  • Lugege oma otsinguga seotud teaduspublikatsioone
  • Otsige ravimtaimi nende mõju järgi
  • Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel

Google Play badgeApp Store badge